Wrinkle-smoothing and anti-wrinkle eye capsule essence based on polypeptide nanocapsule and preparation method of wrinkle-smoothing and anti-wrinkle eye capsule essence

Abstract

The invention relates to the field of cosmetics, in particular to a wrinkle-smoothing and anti-wrinkle eye capsule essence based on polypeptide nanocapsules and a preparation method of the wrinkle-smoothing and anti-wrinkle eye capsule essence, active ingredients are wrapped in a nanoscale carrier by adopting a polypeptide nanocapsule technology, and permeability and stability of the essence in skin are remarkably improved. The essence is combined with various moisturizing, nourishing and repairing components, can deeply moisten and repair eye skin, and improves fine wrinkles, wrinkles and loose phenomena. In the preparation process, the ratio of an oil phase to a water phase, the temperature and the stirring speed are strictly controlled, and the stable emulsification effect is ensured. Through the application of the polypeptide nanocapsule, the essence can provide a lasting anti-aging effect, and the compactness and elasticity of eye skin are remarkably improved. The product is mild and non-irritant, is suitable for long-term use, and meets the requirements of modern consumers on efficient, safe and comfortable eye care.

Description

Technical Field

[0001] This invention relates to the field of cosmetics, specifically to a wrinkle-smoothing and anti-wrinkle eye capsule essence based on polypeptide nanocapsules and its preparation method. Background Technology

[0002] As we age, fine lines, wrinkles, and sagging skin gradually appear around the eyes. Because the skin around the eyes is thin and lacks sufficient fat layer support, it is particularly susceptible to external environmental influences, exacerbating these aging problems. Traditional eye care products, such as eye creams and serums, typically alleviate these issues primarily through surface moisturizing and hydration. However, this approach often only temporarily improves the skin's surface condition and cannot fundamentally address the structural problems of aging around the eyes, especially in terms of deep wrinkles, skin laxity, and decreased elasticity.

[0003] Most existing eye care products rely on moisturizing and antioxidant ingredients, which can improve skin elasticity and softness through hydration. However, because these active ingredients have poor permeability, they struggle to reach the basal layer of the skin to exert their effects, thus failing to effectively address the root causes of aging around the eyes. While these ingredients can alleviate fine lines and dryness in the short term, they cannot improve deeper signs of aging around the eyes.

[0004] In recent years, with the development of nanotechnology and peptide technology, new eye care products have begun to incorporate peptide nanocapsule technology. This technology, by encapsulating active ingredients in nanocapsules, effectively improves their permeability and stability in the skin. Peptide nanocapsules can carry active ingredients through the stratum corneum, reaching deeper layers of the skin to promote skin repair and regeneration, reduce fine lines and wrinkles, and help restore skin firmness and elasticity. The application of this technology provides a more effective solution for eye care products.

[0005] However, existing eye serums still face several challenges when applying peptide nanocapsule technology. First, while peptide nanocapsules can enhance the permeability of active ingredients, achieving a stable, long-term release of these ingredients remains a key issue. Many peptide nanocapsule systems fail to achieve the desired sustained-release effect after contact with the skin, resulting in the rapid release or inactivation of active ingredients within a short period, thus affecting the overall effectiveness. Second, although nanotechnology can improve ingredient permeability, current technologies primarily rely on a limited number of moisturizing and anti-aging ingredients, making it difficult to address the multifaceted problems of aging around the eyes, such as deep wrinkles, skin laxity, and dullness. Finally, some active ingredients may irritate sensitive skin upon penetration, especially in the eye area; ensuring the gentleness of eye serums and minimizing allergic reactions remains a technical challenge.

[0006] Therefore, the market urgently needs an innovative eye serum product that can effectively enhance the permeability, stability, and long-lasting effects of active ingredients through peptide nanocapsule technology. Through optimized formulation, it should not only provide excellent moisturizing and hydrating effects but also significantly improve the firmness, elasticity, and deep wrinkles of the skin around the eyes. Simultaneously, the product should be gentle and non-irritating, suitable for long-term use, and meet consumers' needs for efficient, safe, and comfortable eye care. Summary of the Invention

[0007] To overcome the shortcomings of existing eye care products in improving eye aging, fine lines, wrinkles, and skin laxity, this invention aims to provide a wrinkle-reducing and anti-wrinkle eye capsule essence based on polypeptide nanocapsules and its preparation method. This essence utilizes polypeptide nanocapsule technology, combined with highly effective active ingredients, to enhance the permeability and stability of the active ingredients, thereby achieving a longer-lasting anti-aging effect. The technical solution of this invention enhances the skin's penetration ability by encapsulating active ingredients in polypeptide nanocapsules, while using precisely proportioned moisturizing, nourishing, and repairing ingredients to improve the essence's stability and efficacy. The entire preparation process strictly controls the ratio of the oil phase to the water phase, temperature, and stirring speed to ensure emulsification and stability. The final eye essence significantly improves fine lines, wrinkles, and skin laxity around the eyes. The beneficial effects of this invention lie in the application of polypeptide nanocapsule technology, which significantly enhances the permeability and repair effect of the skin around the eyes, effectively improving signs of aging.

[0008] The objective of this invention can be achieved through the following technical solutions: A wrinkle-reducing and anti-wrinkle eye capsule essence based on polypeptide nanocapsules, the essence comprising the following raw materials in parts by weight: isododecane 59.16-59.66 parts; polydimethylsiloxane 34.5-35.5 parts; octyl polymethylsiloxane and polydimethylsiloxane crosspolymer 4.5-5.5 parts; ascorbate tetraisopalmitate 0.2-0.3 parts; meadowfoam seed oil 0.1-0.12 parts; myrtle oil 0.1-0.12 parts; milk thistle seed oil 0.1-0.12 parts; blueberry seed oil 0.1-0.12 parts; fragrance 0.09-0.11 parts; isosorbide dimethyl ether and hydroxypinazone retinate 0.009-0.011 parts; 1,2 - Hexanediol and fullerene 0.009–0.011 parts; Caprylic triglyceride, polyglycerol-6 polyricinoleate, polyglycerol-4 laurate, water and arginine polypeptide 0.009–0.011 parts; Neopentyl glycol dicaprylate, polyglycerol-2 isostearate, 1,2-hexanediol, 1,2-pentanediol, ethylhexylglycerin, lactic acid, palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 0.009–0.011 parts; Caprylic triglyceride, pistachio seed oil, Aralia elata kernel oil and Marshmallow extract 0.009–0.011 parts; Bisabolol 0.000009–0.000011 parts; Cyperus rotundus root oil 0.000009–0.000011 parts.

[0009] Optionally, the mass ratio of octyl polymethylsiloxane to polydimethylsiloxane crosslinked polymer is 1:1.5 to 2.

[0010] Optionally, the mass ratio of isosorbide dimethyl ether to hydroxypinazone retinate is 1:0.05 to 0.1.

[0011] Optionally, the mass ratio of 1,2-hexanediol to fullerene is 1:0.001 to 0.005.

[0012] Optionally, the mass ratio of caprylic triglyceride, polyglycerol-6 polyricinoleate, polyglycerol-4 laurate, water, and arginine peptide is 1:0.3-0.5:0.05-0.1:1:0.01-0.05.

[0013] Optionally, the mass ratio of neopentyl glycol dioctanoate, polyglycerol-2 isostearate, 1,2-hexanediol, 1,2-pentanediol, ethylhexylglycerin, lactic acid, palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 is 1:0.1-0.2:0.05-0.1:0.05-0.1:0.05-0.1:1:0.01-0.02:0.01-0.02.

[0014] Optionally, the mass ratio of caprylic acid triglyceride, pistachio seed oil, argan kernel oil and marshmallow extract is 1:0.05-0.1:0.05-0.1:0.01-0.05.

[0015] Optionally, a method for preparing a wrinkle-reducing and anti-wrinkle eye capsule essence based on polypeptide nanocapsules includes the following steps: S1, add the following oily components sequentially to the mixing container: isododecane, polydimethylsiloxane, octyl polymethylsiloxane and polydimethylsiloxane crosspolymer, ascorbate tetraisopalmitate, meadowfoam seed oil, myrtle oil, milk thistle seed oil, blueberry seed oil, fragrance, isosorbide dimethyl ether and hydroxypinazone retinate, 1,2-hexanediol and fullerene, caprylic triglyceride, polyglycerol-6 polyricinoleate, polyglycerol-4 laurate, pistachio seed oil. Argan kernel oil, stirred at low temperature to ensure all oily components are completely mixed; add the following aqueous components and active ingredients sequentially to another container and mix to form an aqueous phase: water, arginine peptides, neopentyl glycol dicaprylate, polyglycerol-2 isostearate, 1,2-hexanediol, 1,2-pentanediol, ethylhexylglycerin, lactic acid, palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7, bisabolol, and Cyperus rotundus root oil, ensuring the aqueous components and active ingredients are completely dissolved to form a homogeneous solution; S2. Add the oil phase and water phase to the stirrer, start the stirrer, and stir to ensure that the solution is evenly mixed. While stirring, add the cross-linking polymer until a stable emulsion is formed. This is the anti-wrinkle eye capsule essence based on peptide nanocapsules. Ensure good emulsification.

[0016] Optionally, the ratio of oil phase to water phase in step S1 is 1:1.

[0017] Optionally, in step S2, the stirring speed is adjusted to 48–55 rpm.

[0018] The beneficial effects of this invention are: This invention employs a "peptide-fullerene-isosorbitan dimethyl ether" composite nanocapsule in synergy with a specific silicone oil system / ratio window to stabilize the droplet size at 150–160 nm and the particle size distribution index ≤ 0.28. Under a 1:1 oil-water ratio and a three-pass homogenization process at 100 MPa, a narrow distribution and non-oil separation appearance can be obtained without relying on conventional PEG emulsifiers. Nitrogen-filled soft capsule encapsulation significantly inhibits photo / oxygen degradation, and the activity retention rate is ≥ 95% after 90 days of accelerated processing. This demonstrates that the composite nanocapsule and ratio window substantially improve stability and delivery efficiency. Attached Figure Description

[0019] The invention will now be further described with reference to the accompanying drawings.

[0020] Figure 1 A comparison of median particle size for samples with different formulation ratios; Figure 2 A comparison chart of particle size distribution indices for samples with different proportions; Figure 3 Comparison of dynamic viscosity results at 25℃ for samples with different ratios; Figure 4 This is a comparison chart showing the activity retention rates of samples with different ratios. Detailed Implementation

[0021] The present invention will be further described below with reference to specific embodiments. However, the present invention is not limited to the following embodiments. Equivalent adjustments made without departing from the spirit and essence of the present invention should also be considered to fall within the protection scope of the present invention.

[0022] Example 1 Formula composition: 59.66 parts isododecane; 35.5 parts polydimethylsiloxane; 5.5 parts octyl polymethylsiloxane and polydimethylsiloxane crosspolymer; 0.3 parts ascorbic acid tetraisopalmitate; 0.12 parts meadowfoam seed oil; 0.12 parts myrtle oil; 0.12 parts milk thistle seed oil; 0.12 parts blueberry seed oil; 0.11 parts fragrance; 0.011 parts isosorbide dimethyl ether and hydroxypinazone retinate; 0.011 parts 1,2-hexanediol and fullerene; 0.011 parts caprylic acid triglyceride; 0.011 parts polyglycerol-6 polyricinoleate. Polyglycerol-4-laurate 0.011 parts; Pistachio seed oil 0.011 parts; Argan kernel oil 0.011 parts; Water 0.011 parts; Arginine polypeptide 0.011 parts; Neopentyl glycol dioctanoate 0.011 parts; Polyglycerol-2-isostearate 0.011 parts; 1,2-hexanediol 0.011 parts; 1,2-pentanediol 0.011 parts; Ethylhexylglycerin 0.011 parts; Lactic acid 0.011 parts; Palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 0.011 parts; Bisabolol 0.000011 parts; Cyperus rotundus root oil 0.000011 parts; Preparation method: S1, Preparation of oil and aqueous phases The emulsifying tank was maintained at 35°C, under vacuum of -0.04 MPa, and purged with a trace amount of nitrogen. 59.66 parts of isododecane, 35.5 parts of polydimethylsiloxane, and 5.5 parts of octyl polymethylsiloxane / polydimethylsiloxane crosspolymer were added sequentially and pre-stirred at 50 rpm for 10 min, followed by high shear at 2000 rpm for 5 min to ensure complete swelling of the siloxane. Then, 0.3 parts of ascorbic acid tetraisopalmitate, 0.12 parts each of meadowfoam seed oil, myrtle oil, milk thistle seed oil, and blueberry seed oil, and 0.11 parts of fragrance were added while maintaining the temperature at 35°C. The mixture was stirred at 300 rpm for 5 min to obtain a clear oil phase. The aqueous phase was dissolved sequentially in water for injection at 25°C at 80 rpm. Amino acid peptides, lactic acid, ethylhexylglycerin, and 1,2-diols were added, and the mixture was heated to 30°C. 0.011 parts each of neopentyl glycol dioctanoate and polyglycerol-2 isostearate were then added. The mixture was subsequently cooled to 4°C under ice bath conditions to dissolve 0.011 parts of palmitoyl tripeptide-1 / palmitoyl tetrapeptide-7. Finally, 0.000011 parts each of bisabolol (co-soluble with polyglycerol-6 polyricinoleate) and Cyperus rotundus root oil were added dropwise to obtain a clear aqueous phase. 0.011 parts of isosorbide dimethyl ether / hydroxypinazone retinate and 0.011 parts of fullerene were dissolved at 28°C and 300 rpm, and then sonicated at 200 W for 8 min. Finally, the mixture was mixed with 0.011 parts of 1,2-hexanediol to form an active composite lipid phase for later use. S2, Emulsification, Homogenization and Post-processing The oil phase and aqueous phase were simultaneously pumped into the emulsification tank at a mass ratio of 1:1 and emulsified at 6000 rpm for 5 minutes to obtain a crude emulsion. The active composite lipid phase was then slowly added in three equal portions, with each addition followed by shearing at 8000 rpm for 3 minutes, for a total shearing time of 10 minutes. The crude emulsion was then fed into a high-pressure homogenizer and homogenized three times at 25°C and 120 MPa to obtain emulsion D. 50 The sample was approximately 150 nm in size with a particle size distribution index of <0.25. It was then degassed under a vacuum of -0.08 MPa for 15 min, while simultaneously cooling the jacket to 25°C with 12°C cold water and stirring at 50 rpm. After testing, the emulsion had a pH of 5.8, a viscosity of 300 mPa·s, and a total bacterial count below 100 CFU·g⁻¹. It was then filled into 7 mm seaweed soft capsules (0.35 g per capsule) under 0.05 MPa nitrogen protection, heat-sealed at 65°C and 0.30 MPa, cultured at 25°C / 60% RH for 48 h, and bottled. The finished product was stored in a cool, dark place at 15–25°C.

[0023] Example 2 Formula composition: Isododecane 59.41 parts; polydimethylsiloxane 35 parts; octyl polymethylsiloxane and polydimethylsiloxane crosspolymer 5 parts; ascorbate tetraisopalmitate 0.25 parts; meadowfoam seed oil 0.11 parts; myrtle oil 0.11 parts; milk thistle seed oil 0.11 parts; blueberry seed oil 0.11 parts; fragrance 0.1 parts; isosorbide dimethyl ether and hydroxypinazone retinate 0.01 parts; 1,2-hexanediol and fullerene 0.01 parts; caprylic triglyceride 0.01 parts; polyglycerol-6 polyricinoleate 0.01 parts ; Polyglycerol-4-laurate 0.01 parts; Pistachio seed oil 0.01 parts; Argan kernel oil 0.01 parts; Water 0.01 parts; Arginine polypeptide 0.01 parts; Neopentyl glycol dioctanoate 0.01 parts; Polyglycerol-2-isostearate 0.01 parts; 1,2-hexanediol 0.01 parts; 1,2-pentanediol 0.01 parts; Ethylhexylglycerin 0.01 parts; Lactic acid 0.01 parts; Palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 0.01 parts; Bisabolol 0.00001 parts; Cyperus rotundus root oil 0.00001 parts; Preparation method: S1, Preparation of oil and aqueous phases In an emulsifying vessel at 33°C and a vacuum of -0.04 MPa, 59.41 parts of isododecane, 35.00 parts of polydimethylsiloxane, and 5.00 parts of a crosslinked siloxane system were slowly added. The mixture was pre-stirred at 50 rpm for 8 minutes, then sheared at 1500 rpm for 4 minutes. Next, 0.25 parts of ascorbic acid tetraisopalmitate and 0.11 parts each of four vegetable oils were added, followed by 0.10 parts of fragrance. The mixture was stirred at 300 rpm for 3 minutes to obtain a homogeneous oil phase. The aqueous phase was dissolved in water for injection at 23°C, and arginine peptides were dissolved sequentially at 80 rpm. Lactic acid and other water-soluble additives were added in 0.010 parts each; a mixture of neopentyl glycol dioctanoate and polyglycerol-2 isostearate was added at 30°C, and then palmitoyl tripeptide-1 / palmitoyl tetrapeptide-7 was dissolved in an ice bath at 8°C; bisabolol and Cyperus rotundus root oil, 0.000010 parts each, were slowly added dropwise after being co-dissolved, and the aqueous phase was kept clear; the active complex lipid phase was prepared by sonication at 28°C for 8 minutes using isosorbide dimethyl ether / hydroxypinazone retinate, fullerene and 1,2-hexanediol in a ratio of 0.010 parts each. S2, Emulsification, Homogenization and Post-processing The oil phase and aqueous phase were simultaneously fed into the emulsification tank at a 1:1 ratio and emulsified at 5500 rpm for 5 minutes under high shear. The active composite lipid phase was added at once and sheared at 7500 rpm for 8 minutes. The emulsion was then fed into a high-pressure homogenizer and circulated three times at 25°C and 100 MPa. The median particle size was 155 nm. After homogenization, the emulsion was degassed at -0.07 MPa for 10 minutes. The temperature was then lowered from 12°C to 24°C in the jacket and gently stirred. The final product had a pH of 5.9 and a viscosity of 280 mPa·s, which met the microbial limit requirements. Subsequently, the product was filled, sealed, cultured, and packaged under nitrogen protection, following the same process as in Example 1.

[0024] Example 3 Formula composition: 59.16 parts isododecane; 34.5 parts polydimethylsiloxane; 4.5 parts octyl polymethylsiloxane and polydimethylsiloxane crosspolymer; 0.2 parts ascorbic acid tetraisopalmitate; 0.1 parts meadowfoam seed oil; 0.1 parts myrtle oil; 0.1 parts milk thistle seed oil; 0.1 parts blueberry seed oil; 0.09 parts fragrance; 0.009 parts isosorbide dimethyl ether and hydroxypinazone retinate; 0.009 parts 1,2-hexanediol and fullerene; 0.009 parts caprylic acid triglyceride; 0.009 parts polyglycerol-6 polyricinoleate; polyglycerol... Oil-4 laurate 0.009 parts; Pistachio seed oil 0.009 parts; Argan kernel oil 0.009 parts; Water 0.009 parts; Arginine polypeptide 0.009 parts; Neopentyl glycol dioctanoate 0.009 parts; Polyglycerol-2 isostearate 0.009 parts; 1,2-hexanediol 0.009 parts; 1,2-pentanediol 0.009 parts; Ethylhexylglycerin 0.009 parts; Lactic acid 0.009 parts; Palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 0.009 parts; Bisabolol 0.000009 parts; Cyperus rotundus root oil 0.000009 parts; Preparation method: S1, Preparation of oil and aqueous phases The emulsifying tank was set to 30°C and evacuated to -0.04 MPa with nitrogen. 59.16 parts of isododecane, 34.50 parts of polydimethylsiloxane, and 4.50 parts of crosslinked siloxane system were added, and the mixture was stirred at 40 rpm for 10 min, followed by shearing at 1200 rpm for 6 min until complete swelling. Immediately afterwards, 0.20 parts of ascorbic acid tetraisopalmitate, 0.10 parts each of four vegetable oils, and 0.09 parts of fragrance were added, and the mixture was stirred at 250 rpm for 3 min to obtain a clear oil phase. The aqueous phase was then separated. Using 0℃ water for injection as a base, 0.009 parts each of arginine polypeptide and all water-soluble excipients were dissolved at 70 rpm. After being added to the ester co-solution at 30℃, palmitoyl tripeptide-1 / palmitoyl tetrapeptide-7 were dissolved in an ice bath at 4℃. Then, 0.000009 parts each of bisabolol and Cyperus rotundus root oil, 0.009 parts each of isosorbide dimethyl ether / hydroxypinazone retinate, fullerene and 1,2-hexanediol were added dropwise. After sonication at 28℃ for 8 min, an active composite lipid phase was prepared. S2, Emulsification, Homogenization and Post-processing The oil phase and aqueous phase were pumped into the emulsification tank at a 1:1 mass ratio and emulsified at 5000 rpm for 6 minutes under high shear to obtain a crude emulsion. The active composite lipid phase was added in two batches, with each addition followed by shearing at 7000 rpm for 9 minutes. The emulsion was then circulated three times under high pressure homogenization at 25°C and 90 MPa to obtain emulsion D. 50 The particles were approximately 160 nm in size with a particle size distribution index of 0.28. After the machine was stopped, the emulsion was transferred to a degassing tank and degassed under vacuum at -0.06 MPa for 12 min. Simultaneously, the temperature was lowered to 23°C with cooling water at 12°C and gently stirred at 50 rpm. The pH was measured to be 6.0, the viscosity to be 260 mPa·s, and the total bacterial count to be <100 CFU·g⁻¹. No stratification was observed after 60 days. The formulation was then prepared and stored according to the capsule filling, sealing, culture, and packaging process described in Example 1.

[0025] Comparative Example 1 Formula composition: 59.41 parts isododecane; 35 parts polydimethylsiloxane; 5 parts octyl polymethylsiloxane and polydimethylsiloxane crosspolymer; 0.25 parts ascorbic acid tetraisopalmitate; 0.11 parts meadowfoam seed oil; 0.11 parts myrtle oil; 0.11 parts milk thistle seed oil; 0.11 parts blueberry seed oil; 0.1 parts fragrance; 0.01 parts isosorbide dimethyl ether and hydroxypinazone retinate; 0.01 parts 1,2-hexanediol and fullerene; 0.01 parts caprylic acid triglyceride; polyglycerol. -6 polyricinoleate 0.01 parts; polyglycerol-4 lauryl ester 0.01 parts; pistachio seed oil 0.01 parts; argan kernel oil 0.01 parts; water 0.02 parts; arginine peptide 0.01 parts; neopentyl glycol dioctanoate 0.01 parts; polyglycerol-2 isostearate 0.01 parts; 1,2-hexanediol 0.01 parts; 1,2-pentanediol 0.01 parts; ethylhexylglycerin 0.01 parts; lactic acid 0.01 parts; bisabolol 0.00001 parts; sedge root oil 0.00001 parts; S1, Preparation of oil and aqueous phases The process temperature, vacuum level, rotation speed, and time were the same as in Example 2. The dissolution order in the aqueous phase remained unchanged, except that palmitoyl tripeptide-1 / palmitoyl tetrapeptide-7 was not added in the ice bath stage; instead, an equal volume of water for injection was directly added to maintain a constant total proportion. All other steps were completely identical.

[0026] S2, Emulsification, Homogenization and Post-processing The emulsification and shearing procedures, homogenization conditions, and defoaming / cooling parameters were the same as in Example 2. The final emulsion particle size D... 50 The particle size distribution index increased to 0.34, the viscosity decreased to 240 mPa·s, and slight stratification appeared after 60 days.

[0027] Comparative Example 2 Formula composition: 59.41 parts isododecane; 35 parts polydimethylsiloxane; 5 parts octyl polymethylsiloxane and polydimethylsiloxane crosspolymer; 0.25 parts ascorbic acid tetraisopalmitate; 0.11 parts meadowfoam seed oil; 0.11 parts myrtle oil; 0.11 parts milk thistle seed oil; 0.11 parts blueberry seed oil; 0.1 parts fragrance; 0.01 parts isosorbide dimethyl ether and hydroxypinazone retinate; 0.01 parts 1,2-hexanediol; 0.01 parts caprylic acid triglyceride; polyglycerol-6 polyricinole. 0.01 parts of esters; 0.01 parts of polyglycerol-4 laurate; 0.01 parts of pistachio seed oil; 0.01 parts of Argan kernel oil; 0.01 parts of water; 0.01 parts of arginine polypeptide; 0.01 parts of neopentyl glycol dioctanoate; 0.01 parts of polyglycerol-2 isostearate; 0.01 parts of 1,2-pentanediol; 0.01 parts of ethylhexylglycerin; 0.01 parts of lactic acid; 0.01 parts of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7; 0.00001 parts of bisabolol; 0.00001 parts of Cyperus rotundus root oil.

[0028] S1, Preparation of oil and aqueous phases The process operation, temperature, vacuum, and stirring parameters were completely consistent with those in Example 2; the active composite lipid phase contained only isosorbide dimethyl ether / hydroxypinazone retinate and 1,2-hexanediol, without the addition of fullerene, and the ultrasonic conditions remained unchanged. S2, Emulsification, Homogenization and Post-processing The emulsification, shearing, and high-pressure homogenization steps were the same as in Example 2; defoaming was performed at –0.07 MPa for 10 min, followed by cooling to a final temperature of 24°C. The resulting emulsion D... 50 The particle size was 178 nm, the particle size distribution index was 0.30, and the pH was 5.9, but the antioxidant stability test showed that the activity retention rate dropped to 86%, and slight fading occurred.

[0029] Performance testing 1. Particle size distribution testing method Take 0.10 g of capsule contents, dilute to 10 mL with Milli-Q pure water, and stir magnetically at 25°C for 2 min, then place in a Branson 2510 ultrasonic bath for 30 s to eliminate initial agglomeration. Inject the dispersion into the sample cell of a Malvern Mastersizer 3000 laser scattering particle size analyzer (UK), with a detection temperature of 25°C, refractive index parameters set to 1.46 / 0.01, and a scan time of 60 s; the median particle size and particle size distribution index are automatically output, and each sample is tested in triplicate.

[0030] 2. Rheology-Viscosity Testing Methods Accurately measure 10 mL of sample and place it in a 25℃ constant temperature bath for equilibration for 10 min. Then transfer it to a Brookfield DV3T digital display rotational viscometer (USA), perform a pre-shear at 60 rpm for 30 s, and record a stable reading for 60 s. After measurement, clean the rotor with 0.5% nonylphenol polyoxyethylene ether solution and rinse thoroughly with pure water. Each sample was measured three times.

[0031] 3. Accelerated stability testing method The encapsulated products were placed in a Memmert HPP260 constant temperature and humidity chamber (Germany) at 40℃ and 75%RH for 90 days. Every 30 days, three capsules were randomly selected and cut to observe their appearance and olfactory characteristics. The particle size was re-determined using a Mastersizer 3000. The active content was measured using a Waters 2695 HPLC system with a Photodiode Array detector, a C18 column (250 mm × 4.6 mm, 5 µm), a flow rate of 1.0 mL·min⁻¹, gradient elution, and the peak area was recorded and compared with the initial value to calculate the retention rate.

[0032] Table 1 Performance Test Results

[0033] After comprehensively comparing four indicators—median particle size, particle size distribution index, viscosity at 25°C, and activity retention rate after 90 days—it can be seen that Example 2 exhibits the best performance across all indicators. Regarding particle characteristics, Figure 1 and Figure 2 The median particle size of Example 2 was 150 nm, and the particle size distribution index was 0.25, which were superior to those of Examples 1, 3, and the two comparative examples. Smaller particle size and more uniform distribution indicate that the emulsion droplets are sufficiently stabilized by the nanocapsule network and are not prone to aggregation; while the particle size and particle size distribution index of Comparative Examples 1 and 2 were significantly increased, indicating that the emulsion structure tended to be loose after the loss of key activities.

[0034] Rheological properties and storage stability also show the same trend. Figure 3 In Example 2, the dynamic viscosity at 25°C was maintained at 300 mPa·s, and the viscoelasticity was moderate, which can ensure the feel of capsule filling and skin application. Figure 4 Even after a 90-day accelerated aging test, the active content remained at 95%, demonstrating excellent antioxidant and physical stability. In contrast, Comparative Examples 1 and 2 showed decreased viscosity and activity retention rates below 90%, indicating that the lack of dipeptides or fullerenes weakened the system's stability.

[0035] Based on the four performance indicators, Example 2 showed the best performance due to the enhanced stability of the emulsion droplets by the dipeptide network and the slowing down of oxidative degradation by the fullerene. The synergistic effect of the complete formulation also made all examples better than the comparative samples overall.

Claims

1. A wrinkle-reducing and anti-wrinkle eye capsule essence based on polypeptide nanocapsules, characterized in that, The essence comprises the following raw materials in parts by weight: isododecane 59.16–59.66 parts; polydimethylsiloxane 34.5–35.5 parts; octyl polymethylsiloxane and polydimethylsiloxane crosspolymer 4.5–5.5 parts; ascorbic acid tetraisopalmitate 0.2–0.3 parts; meadowfoam seed oil 0.1–0.12 parts; myrtle oil 0.1–0.12 parts; milk thistle seed oil 0.1–0.12 parts; blueberry seed oil 0.1–0.12 parts; fragrance 0.09–0.11 parts; isosorbide dimethyl ether and hydroxypinazone retinate 0.0 0.009–0.011 parts; 1,2-hexanediol and fullerene 0.009–0.011 parts; caprylic acid triglyceride, polyglycerol-6 polyricinoleate, polyglycerol-4 laurate, water and arginine polypeptide 0.009–0.011 parts; neopentyl glycol dicaprylate, polyglycerol-2 isostearate, 1,2-hexanediol, 1,2-pentanediol, ethylhexylglycerin, lactic acid, palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 0.009–0.011 parts; caprylic acid triglyceride, pistachio seed oil, argan kernel oil and marshmallow extract 0.009–0.011 parts; Bisabolol 0.000009–0.000011 parts; Cyperus rotundus root oil 0.000009–0.000011 parts.

2. The anti-wrinkle eye capsule essence based on polypeptide nanocapsules according to claim 1, characterized in that, The mass ratio of the octyl polymethylsiloxane to the polydimethylsiloxane crosslinked polymer is 1:1.5 to 2.

3. The anti-wrinkle eye capsule essence based on polypeptide nanocapsules according to claim 1, characterized in that, The mass ratio of isosorbide dimethyl ether to hydroxypinazone retinate is 1:0.05 to 0.

1.

4. The anti-wrinkle eye capsule essence based on polypeptide nanocapsules according to claim 1, characterized in that, The mass ratio of 1,2-hexanediol to fullerene is 1:0.001 to 0.

005.

5. The anti-wrinkle eye capsule essence based on polypeptide nanocapsules according to claim 1, characterized in that, The mass ratio of caprylic triglyceride, polyglycerol-6 polyricinoleate, polyglycerol-4 laurate, water, and arginine polypeptide is 1:0.3-0.5:0.05-0.1:1:0.01-0.

05.

6. The anti-wrinkle eye capsule essence based on polypeptide nanocapsules according to claim 1, characterized in that, The mass ratio of neopentyl glycol dioctanoate, polyglycerol-2 isostearate, 1,2-hexanediol, 1,2-pentanediol, ethylhexylglycerin, lactic acid, palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 is 1:0.1-0.2:0.05-0.1:0.05-0.1:0.05-0.1:1:0.01-0.02:0.01-0.

02.

7. The anti-wrinkle eye capsule essence based on polypeptide nanocapsules according to claim 1, characterized in that, The mass ratio of caprylic acid triglyceride, pistachio seed oil, argan kernel oil and marshmallow extract is 1:0.05-0.1:0.05-0.1:0.01-0.

05.

8. A method for preparing a wrinkle-reducing and anti-wrinkle eye capsule essence based on polypeptide nanocapsules, wherein the wrinkle-reducing and anti-wrinkle eye capsule essence based on polypeptide nanocapsules is as described in any one of claims 1 to 7, characterized in that, Includes the following steps: S1, add the following oily components sequentially to the mixing container: isododecane, polydimethylsiloxane, octyl polymethylsiloxane and polydimethylsiloxane crosspolymer, ascorbate tetraisopalmitate, meadowfoam seed oil, myrtle oil, milk thistle seed oil, blueberry seed oil, fragrance, isosorbide dimethyl ether and hydroxypinazone retinate, 1,2-hexanediol and fullerene, caprylic triglyceride, polyglycerol-6 polyricinoleate, polyglycerol-4 laurate. Pistachio seed oil and Argan kernel oil were stirred at low temperature to ensure that all oily components were completely mixed. The following aqueous components and active ingredients were added to another container in sequence and mixed to form an aqueous phase: water, arginine peptides, neopentyl glycol dioctanoate, polyglycerol-2 isostearate, 1,2-hexanediol, 1,2-pentanediol, ethylhexylglycerin, lactic acid, palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7, bisabolol, and Cyperus rotundus root oil to form a homogeneous solution. S2. Add the oil phase and water phase to the stirrer, start the stirring device, and stir while adding the cross-linking polymer until a stable emulsion is formed. This is the anti-wrinkle eye capsule essence based on peptide nanocapsules.

9. The method for preparing a wrinkle-reducing and anti-wrinkle eye capsule essence based on polypeptide nanocapsules according to claim 1, characterized in that, The ratio of oil phase to water phase in step S1 is 1:

1.

10. The method for preparing a wrinkle-reducing and anti-wrinkle eye capsule essence based on polypeptide nanocapsules according to claim 1, characterized in that, In step S2, the stirring speed is adjusted to 48-55 rpm.

Images